Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies
Open Access
- 25 February 2021
- Vol. 10 (3), 491
- https://doi.org/10.3390/cells10030491
Abstract
Immunotherapy for brain tumors remains elusive, unlike many other cancer types for which it is one of the most promising therapeutic options. Recent studies have comprehensively profiled the immune-landscape of the highly malignant brain tumor, glioblastoma (GBM) in patients and identified novel immune-modulatory targets. However, given that pre-clinical exploration of potential novel therapeutics is primarily performed in immune-competent mice, it is vital to compare the immune-profiling data obtained from syngeneic mouse GBM models with GBM patient samples. This will pave the way for utilizing appropriate clinically relevant mouse GBM models for evaluating novel immune-therapies in pre-clinical settings. Recent brain tumor immune-profiling studies using state-of-the-art time of flight cytometry (CyTOF) analysis compared different human and mouse GBM types and reported immunological distinctions amongst these mouse models. These studies also contrast the immune phenotype of brain tumor patients with commonly used pre-clinical immune-competent mouse models. In this perspective, we provide the outcomes of very recent brain tumor immune-profiling studies and their implications on designing and translating unique, tumor-subtype specific therapeutics.Keywords
Funding Information
- National Institutes of Health (R01-NS107857)
This publication has 33 references indexed in Scilit:
- Prospects of immune checkpoint modulators in the treatment of glioblastomaNature Reviews Neurology, 2015
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer TherapyCancer Cell, 2014
- CSF-1R inhibition alters macrophage polarization and blocks glioma progressionNature Medicine, 2013
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal CancerPLOS ONE, 2013
- Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiformeTumor Biology, 2013
- IDH1 and IDH2 Mutations in GliomasCurrent Neurology and Neuroscience Reports, 2013
- Eosinophils in glioblastoma biologyJournal of Neuroinflammation, 2012
- p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiationNature, 2008
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNature Medicine, 2006
- Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host responseJournal of Leukocyte Biology, 2006